Ipilimumab (YERVOY) ELISA Assay Kit

$1,375.00

The Ipilimumab (YERVOY) ELISA Assay Kit has been developed for the quantitative determination of ipilimumab in serum and plasma samples between the Cmin and Cmax range of concentrations. The Ipilimumab (YERVOY) ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

SKU: IPI-FD-YER Category:

Ipilimumab (YERVOY) ELISA Assay Kit

The Ipilimumab (YERVOY) ELISA Assay Kit is For Research Use Only

Size: 12 x 8 wells
Sensitivity: 3 ng/mL
Standard Range: 0 – 300 ng/ml
Incubation Time: 1 hour 10 minutes
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Name: Yervoy


Assay Background

Ipilimumab is a monoclonal antibody, more specifically a fully humanized IgGl antibody produced in mammalian cell culture, to the cytotoxic T lymphocyteantigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a cell surface molecule that plays an essential role in regulating the adaptative immune response. The activation of T-cells is tightly controlled by two main signals 1) initial binding of tumor-associated antigens on antigen presenting cells to T-cell receptors and 2) subsequent binding of B7 molecules on the antigen presenting cells to CD28 receptors on T cells. After T-cell activation, CTLA-4 will be upregulated and it will compete on the binding between CD28 and B7. The binding between CTLA-4 and B7 interrupts the stimulatory signal which in order blunts T-cell proliferation response.
The action of ipilimumab produces an exacerbated autoimmunity. This is explained as the absence or presence of CTLA-4 can augment or suppress the immune system’s T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining a potent T-cell response against tumor cells.

Assay Principle

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for ipilimumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to ipilimumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of ipilimumab in the sample or standard. Results of samples can be determined directly using the standard curve.


Related Products

Anti-Ipilimumab Yervoy ELISA Assay
Denosumab (Prolia) ELISA Kit
Atezolizumab (Tecentriq) ELISA

Package Inserts


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations